Eliem Therapeutics Inc

NASDAQ ELYM

Download Data

Eliem Therapeutics Inc Average Collection Period 1 year YoY Change (%) for the quarter ending September 20, 2024

Eliem Therapeutics Inc Average Collection Period 1 year YoY Change (%) is NA for the quarter ending September 20, 2024. The average collection period measures the average number of days it takes for a company to collect payments from its customers. It is calculated by dividing 365 by the ratio of revenue to the average of receivables and other current assets. A lower average collection period indicates a more efficient collection process and better cash flow management, while a higher period may suggest delayed payments and potential liquidity challenges. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
NASDAQ: ELYM

Eliem Therapeutics Inc

CEO Mr. Robert W. Azelby M.B.A.
IPO Date Aug. 10, 2021
Location United States
Headquarters 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees 9
Sector Healthcare
Industry Biotechnology
Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email